Drug intelligence / Profile preview

Meningococcal A and C Polysaccharide Conjugate Vaccine (Zhifei Lvzhu)

Development stage: Unknown
Lead developer: Zhifei Biological
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The Meningococcal A and C Polysaccharide Conjugate Vaccine is a bivalent, lyophilized conjugate vaccine developed by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd., a subsidiary of Chongqing Zhifei Biological Products. It is designed to provide immune protection against meningococcal meningitis caused by *Neisseria meningitidis* serogroups A and C. The vaccine contains 10 μg each of purified capsular polysaccharides from serogroups A and C, each chemically conjugated to a tetanus toxoid carrier protein. This conjugation converts the polysaccharides into T-cell dependent antigens, which enhances immunogenicity and induces immunological memory, particularly in infants and young children. Formulated without an adjuvant, the vaccine is administered via intramuscular injection. It received clinical approval from China's State Food and Drug Administration (SFDA) in September 2015 and is indicated for individuals aged 3 months and older.

Other names: Group A and Group C Meningococcal Polysaccharide Conjugate Vaccine (Tetanus Toxoid Conjugate)MenAC-TT (Zhifei Lvzhu)Meningococcal A and C Polysaccharide Conjugate Vaccine

Targets

Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)

Beyond the preview

Go deeper on Meningococcal A and C Polysaccharide Conjugate Vaccine (Zhifei Lvzhu).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meningococcal A and C Polysaccharide Conjugate Vaccine (Zhifei Lvzhu).

Explore the full profile